Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.

Lannett had cautioned that a major restructuring was likely as its operations and balance sheet faltered under a massive debt pile – now that has become a reality, under a proposed plan that will hand the company keys to lenders.

Lannett investors and creditors must brace for further bad news after the Philadelphia-based Rx and OTC drug firm was struck from the New York Stock Exchange.

Lannett investors and creditors must brace for further bad news after the Philadelphia-based player was struck from the New York Stock Exchange.